Literature DB >> 33361363

Self-Administration of Cotinine in Wistar Rats: Comparisons to Nicotine.

Zheng-Ming Ding1, Yong Gao2, Alena M Sentir2, Xiaoying Tan2.   

Abstract

Nicotine is the major addictive component in tobacco. Cotinine is the major metabolite of nicotine and a weak agonist for nicotinic acetylcholine receptors (nAChRs). Nicotine supports self-administration in rodents. However, it remains undetermined whether cotinine can be self-administered. This study aimed to characterize cotinine self-administration in rats, to compare effects of cotinine to those of nicotine, and to determine potential involvement of nAChRs in cotinine's effects. Adult Wistar rats were trained to self-administer cotinine or nicotine (0.0075, 0.015, 0.03, or 0.06 mg/kg per infusion) under fixed-ratio (FR) and progressive-ratio (PR) schedules. Blood nicotine and cotinine levels were determined after the last FR session. Effects of mecamylamine, a nonselective nAChR antagonist, and varenicline, a partial agonist for α4β2* nAChRs, on cotinine and nicotine self-administration were determined. Rats readily acquired cotinine self-administration, responded more on active lever, and increased motivation to self-administer cotinine when the reinforcement requirement increased. Blood cotinine levels ranged from 77 to 792 ng/ml. Nicotine induced more infusions at lower doses during FR schedules and greater breakpoints at higher doses during the PR schedule than cotinine. There was no difference in cotinine self-administration between male and female rats. Mecamylamine and varenicline attenuated nicotine but not cotinine self-administration. These results indicate that cotinine was self-administered by rats. These effects of cotinine were less robust than nicotine and exhibited no sex difference. nAChRs appeared to be differentially involved in self-administration of nicotine and cotinine. These results suggest cotinine may play a role in the development of nicotine use and misuse. SIGNIFICANCE STATEMENT: Nicotine addiction is a serious public health problem. Cotinine is the major metabolite of nicotine, but its involvement in nicotine reinforcement remains elusive. Our findings indicate that cotinine, at doses producing clinically relevant blood cotinine levels, supported intravenous self-administration in rats. Cotinine self-administration was less robust than nicotine. Mecamylamine and varenicline attenuated nicotine but not cotinine self-administration. These results suggest cotinine may play a role in the development of nicotine use and misuse.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33361363      PMCID: PMC7883011          DOI: 10.1124/jpet.120.000367

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  54 in total

1.  Nicotine self-administration in rats.

Authors:  E C Donny; A R Caggiula; S Knopf; C Brown
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

2.  Nicotinic effects of tobacco smoke constituents in nonhuman primates.

Authors:  Rajeev I Desai; Michelle R Doyle; Sarah L Withey; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2016-02-19       Impact factor: 4.530

3.  e-Cigarette Use Among Youth in the United States, 2019.

Authors:  Karen A Cullen; Andrea S Gentzke; Michael D Sawdey; Joanne T Chang; Gabriella M Anic; Teresa W Wang; MeLisa R Creamer; Ahmed Jamal; Bridget K Ambrose; Brian A King
Journal:  JAMA       Date:  2019-12-03       Impact factor: 56.272

4.  Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine.

Authors:  Monica M Arnold; Sandra E Loughlin; James D Belluzzi; Frances M Leslie
Journal:  Neuropharmacology       Date:  2014-06-05       Impact factor: 5.250

5.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

6.  On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons.

Authors:  K Fuxe; B J Everitt; T Hökfelt
Journal:  Pharmacol Biochem Behav       Date:  1979-05       Impact factor: 3.533

7.  A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Authors:  Jerry J Buccafusco; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2009-07-03       Impact factor: 5.858

8.  Binding of optically pure (--)-[3H]nicotine to rat brain membranes.

Authors:  L G Abood; S Grassi; M Costanza
Journal:  FEBS Lett       Date:  1983-06-27       Impact factor: 4.124

9.  Neonatal 6-hydroxydopamine lesions of the frontal cortex in rats: persisting effects on locomotor activity, learning and nicotine self-administration.

Authors:  A H Rezvani; D Eddins; S Slade; D S Hampton; N C Christopher; A Petro; K Horton; M Johnson; E D Levin
Journal:  Neuroscience       Date:  2008-04-16       Impact factor: 3.590

10.  The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats.

Authors:  Kelly J Clemens; Stephanie Caillé; Luis Stinus; Martine Cador
Journal:  Int J Neuropsychopharmacol       Date:  2009-04-15       Impact factor: 5.176

View more
  2 in total

1.  The involvement of mesolimbic dopamine system in cotinine self-administration in rats.

Authors:  Xiaoying Tan; Cynthia M Ingraham; William J McBride; Zheng-Ming Ding
Journal:  Behav Brain Res       Date:  2021-09-23       Impact factor: 3.332

Review 2.  Cotinine: Pharmacologically Active Metabolite of Nicotine and Neural Mechanisms for Its Actions.

Authors:  Xiaoying Tan; Kent Vrana; Zheng-Ming Ding
Journal:  Front Behav Neurosci       Date:  2021-10-21       Impact factor: 3.617

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.